PF-Atlas › Clinical Trials › NCT06747923
SB17170 Phase 2 Trial in IPF Patients
SB17170 · Phase 2
Registry ID
NCT06747923
Phase
Phase 2
Status
Recruiting
Drug / intervention
SB17170
Sponsor
SPARK Biopharma
Start
2025-01-27
Enrollment
30
Locations
5
About this trial
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06747923 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.